Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3465541 | 0.89 | CCR1 (0.39) | CCR1CYP3A4HRH4ROCK1CA2 | |
| SCHEMBL3465451 | 0.89 | CCR1 (0.39) | CCR1CYP3A4HRH4ROCK1CA2 | |
| SCHEMBL3465322 | 0.89 | CCR1 (0.39) | CCR1CYP3A4HRH4ROCK1CA2 | |
| SCHEMBL3465203 | 0.88 | CCR1 (0.35) | CCR1CYP3A4ADRB3HRH4 | |
| SCHEMBL3439409 | 0.86 | CCR1 (0.38) | CCR1CYP3A4LOXL2ADRB3HRH4 | |
| SCHEMBL3465973 | 0.86 | CCR1 (0.38) | CCR1CYP3A4LOXL2ADRB3HRH4 | |
| SCHEMBL3466040 | 0.85 | LMNA (0.35) | CCR1CYP3A4ADRB3ROCK1 | |
| Hydrochloric Acid SCHEMBL567868 | 0.84 | CCR1 (0.37) | CCR1CYP3A4LOXL2HRH4ROCK1 | |
| Hydrochloric Acid SCHEMBL27827247 | 0.84 | CCR1 (0.37) | CCR1CYP3A4LOXL2HRH4ROCK1 | |
| SCHEMBL3465668 | 0.84 | CCR1 (0.35) | CCR1CYP3A4ADRB3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | CCR1 1/4885CYP3A4 2075/4885LOXL2 3029/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | CCR1 1/4885CYP3A4 1429/4885LOXL2 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.